{"id":"tlc599","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of TLC599 is not publicly available, but it is believed to work by inhibiting cancer cell growth and inducing apoptosis. The liposomal formulation is designed to improve the delivery and efficacy of the chemotherapeutic agent.","oneSentence":"TLC599 is a liposomal formulation of a chemotherapeutic agent.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:38:59.534Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various types of cancer"}]},"trialDetails":[{"nctId":"NCT03754049","phase":"PHASE2","title":"A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Taiwan Liposome Company","startDate":"2019-01-21","conditions":"Osteoarthritis of the Knee","enrollment":102},{"nctId":"NCT04123561","phase":"PHASE3","title":"Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain","status":"COMPLETED","sponsor":"Taiwan Liposome Company","startDate":"2019-11-26","conditions":"Osteoarthritis of the Knee","enrollment":504},{"nctId":"NCT03005873","phase":"PHASE2","title":"Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients","status":"COMPLETED","sponsor":"Taiwan Liposome Company","startDate":"2017-03-16","conditions":"Osteoarthritis of the Knee","enrollment":76},{"nctId":"NCT02803307","phase":"PHASE1, PHASE2","title":"Single-Dose Administration Trial of TLC599 in Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Taiwan Liposome Company","startDate":"2015-06","conditions":"Osteoarthritis of the Knee","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TLC599 Injection"],"phase":"phase_3","status":"active","brandName":"TLC599","genericName":"TLC599","companyName":"Taiwan Liposome Company","companyId":"taiwan-liposome-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TLC599 is a liposomal formulation of a chemotherapeutic agent. Used for Treatment of various types of cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}